-1750786027006.webp&w=3840&q=75)
2025 MLS Nashville | Prostate Cancer Updates in 2025
Overview
Dr. Vaena reported that phase III evidence for niraparib significantly extends radiographic PFS and enhances quality of life in castration‑sensitive prostate cancer—especially for BRCA‑mutated patients—while he stressed the imperative of germline/somatic testing, optimal timing of PARP‑inhibitor use, and PSMA‑PET guidance to individualize therapy amid ongoing trials.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Daniel Vaena, MD
Date of Release
June 25th, 2025
Related Material
2025 Advances in Oncology | Metastatic Prostate Cancer Therapeutic Landscape: From Biology to Changing Standards of Care
Prostate
1 Chapter
Non-CME Credit Course
2025 Advances in Oncology | Metastatic Hormone Sensitive and Castration Resistant Prostate Cancer in 2025: Longer and Better life
Prostate
1 Chapter
Non-CME Credit Course